X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (318) 318
index medicus (263) 263
raltegravir potassium (247) 247
hiv infections - drug therapy (218) 218
female (174) 174
male (169) 169
adult (161) 161
raltegravir (159) 159
pharmacology & pharmacy (148) 148
infectious diseases (136) 136
middle aged (136) 136
pharmacokinetics (130) 130
pyrrolidinones - pharmacokinetics (121) 121
hiv (101) 101
pyrrolidinones - administration & dosage (91) 91
pyrrolidinones - therapeutic use (90) 90
anti-hiv agents - administration & dosage (88) 88
hiv infections - virology (87) 87
drug interactions (84) 84
microbiology (84) 84
anti-hiv agents - pharmacokinetics (78) 78
hiv integrase inhibitors - pharmacokinetics (78) 78
hiv-1 - drug effects (78) 78
antiviral agents (76) 76
immunology (70) 70
hiv integrase inhibitors - therapeutic use (65) 65
anti-hiv agents - therapeutic use (62) 62
treatment outcome (57) 57
antiretroviral therapy (55) 55
pyrrolidinones - pharmacology (55) 55
safety (54) 54
young adult (53) 53
pyrrolidinones - adverse effects (51) 51
virology (51) 51
hiv infection (49) 49
viral load (49) 49
drug therapy (48) 48
hiv integrase inhibitors - pharmacology (47) 47
hiv integrase inhibitors - administration & dosage (46) 46
drug therapy, combination (45) 45
infection (45) 45
human immunodeficiency virus--hiv (44) 44
hiv integrase inhibitors - adverse effects (43) 43
mk-0518 (43) 43
raltegravir potassium - administration & dosage (43) 43
dosage and administration (42) 42
therapy (42) 42
efficacy (41) 41
hiv-1 (41) 41
integrase inhibitor (41) 41
anti-hiv agents - adverse effects (37) 37
drug resistance, viral (37) 37
raltegravir potassium - pharmacokinetics (37) 37
adolescent (36) 36
aids (35) 35
aids/hiv (35) 35
antiretroviral drugs (35) 35
drug administration schedule (35) 35
integrase inhibitor raltegravir (35) 35
research (35) 35
area under curve (34) 34
integrase (34) 34
hiv-1 - genetics (32) 32
combination therapy (31) 31
health aspects (31) 31
hiv-infected patients (31) 31
treatment-experienced patients (31) 31
pharmacology (30) 30
pyrrolidinones - blood (30) 30
raltegravir potassium - therapeutic use (30) 30
animals (29) 29
cd4 lymphocyte count (28) 28
highly active antiretroviral therapy (28) 28
integrase inhibitors (28) 28
plasma (28) 28
protease inhibitors (28) 28
aged (27) 27
darunavir (27) 27
hiv-1 integrase (27) 27
tenofovir (27) 27
pregnancy (26) 26
tolerability (26) 26
article (25) 25
treatment-naive patients (25) 25
anti-hiv agents - pharmacology (24) 24
care and treatment (24) 24
double-blind (24) 24
efavirenz (24) 24
analysis (23) 23
etravirine (23) 23
healthy-subjects (23) 23
hiv integrase - genetics (23) 23
research article (23) 23
antiretroviral agents (22) 22
hiv-1-infected patients (22) 22
ritonavir (22) 22
administration, oral (21) 21
antiretroviral therapy, highly active - methods (21) 21
clinical trials as topic (21) 21
cross-over studies (21) 21
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Clinical Infectious Diseases, ISSN 1058-4838, 2015, Volume 61, Issue 5, pp. 809 - 816
Journal Article
Clinical Pharmacokinetics, ISSN 0312-5963, 1/2017, Volume 56, Issue 1, pp. 25 - 40
Dolutegravir (DTG), elvitegravir (EVG) and raltegravir (RAL) are members of the latest class of antiretrovirals (ARVs) that have become available to treat... 
Pharmacotherapy | Internal Medicine | Medicine & Public Health | Pharmacology/Toxicology | TWICE-DAILY RALTEGRAVIR | ONCE-DAILY DOLUTEGRAVIR | SERONEGATIVE SUBJECTS | TREATMENT-EXPERIENCED PATIENTS | NON-INFERIORITY TRIAL | CO-FORMULATED ELVITEGRAVIR | DOUBLE-BLIND | PHARMACOLOGY & PHARMACY | INFECTED PATIENTS | RANDOMIZED CONTROLLED-TRIAL | ANTIRETROVIRAL-NAIVE ADULTS | HIV Integrase Inhibitors - pharmacology | Coinfection | Area Under Curve | Humans | Raltegravir Potassium - therapeutic use | Half-Life | Metabolic Clearance Rate | HIV Integrase - metabolism | HIV Integrase Inhibitors - administration & dosage | Liver Failure - metabolism | Drug Interactions | Quinolones - pharmacokinetics | Quinolones - therapeutic use | Female | Heterocyclic Compounds, 3-Ring - pharmacokinetics | Anti-Retroviral Agents - therapeutic use | Raltegravir Potassium - pharmacokinetics | Anti-Retroviral Agents - pharmacokinetics | Anti-Retroviral Agents - pharmacology | HIV Integrase Inhibitors - pharmacokinetics | Renal Insufficiency - metabolism | Pregnancy | Cytochrome P-450 CYP3A - metabolism | Anti-Retroviral Agents - administration & dosage | Heterocyclic Compounds, 3-Ring - therapeutic use | HIV Integrase Inhibitors - therapeutic use | Protein Binding | HIV Infections - drug therapy | Drug Combinations | Antiviral agents | Usage | Care and treatment | Pharmacology | Research | Diagnosis | Pharmacokinetics | Comparative analysis | HIV infection | Cytochrome | Antiretroviral drugs | Enzymes | Infections | Glycoproteins | Metabolism | Patients | Studies | Proteins | Human immunodeficiency virus--HIV | Adults | Drug dosages | Volunteers
Journal Article
by Pressiat, Claire and Hirt, Déborah and Treluyer, Jean-Marc and Zheng, Yi and Morlat, Philippe and Naqvi, Alice and Tran, Laurent and Viard, Jean-Paul and Avettand-Fenoel, Véronique and Rouzioux, Christine and Meyer, Laurence and Cheret, Antoine and Saint-Jacques, Saint-Jacques and Hoen, B and Bourdeaux, C and Delfraissy, J.F and Goujard, C and Amri, I and Fourn, E and Quertainmont, Y and Môle, M and Rami, A and Durel, A and Diemer, M and Parrinello, M and Allégre, T and Lafeuillade, A and Hittinger, G and Lambry, V and Carrerre, M and Philip, G and Duvivier, C and Consigny, P.H and Charlier, C and Shoai, M and Touam, F and Pialoux, G and Slama, L and L'Yavanc, T and Mathurin, P and Adda, A and Berrebi, V and Salmon, D and Chakvetadze, E and Tassadit, T and Ousseima, E and Pietri, P and Levy, Y and Lascaux, A.S and Lelievre, J.D and Giovanna, M and Dominguez, S and Dumont, C and Katlama, C and Valentin, M.A and Seang, S and Schneider, L and Kiorza, N and Chermak, A and Abdallah, S.B and Ben, S and Simon, A and Pichon, F and Pauchard, M and Molina, J.M and Lascoux, C and Ponscarme, D and De Verdiere, N. Colin and Scemla, A and De Castro, N and Rachline, A and Garrait, V and Rozenbaum, W and Ferret, S and Balkan, S and Clavel, F and Tourdjman, M and Lafaurie, M and Aslan, A and Goguel, J and Thierry, S.M and De Lastours, V and Gallien, S and Pavie, J and Delgado, J and Mededji, C and Hôpital, R. Veron and Chennebault, J.M and Vandamme, Y.M and Fialaire, P and Rehaiem, S and Rabier, V and Abgueguen, P and Abel, S and Pierre-Franéois, S and Baringhton, C and Morlat, P and Vandenhende, M.A and Bernard, N and Lacoste, D and ... and OPTIPRIM Study Grp and OPTIPRIM Study Group
Journal of Antimicrobial Chemotherapy, ISSN 0305-7453, 04/2018, Volume 73, Issue 4, pp. 1020 - 1024
Journal Article
Antimicrobial Agents and Chemotherapy, ISSN 0066-4804, 12/2015, Volume 59, Issue 12, pp. 7903 - 7905
Journal Article
Clinical Infectious Diseases, ISSN 1058-4838, 10/2015, Volume 61, Issue 8, pp. 1328 - 1335
Journal Article
Journal of Antimicrobial Chemotherapy, ISSN 0305-7453, 2017, Volume 72, Issue 11, pp. 3167 - 3171
Journal Article
Journal Article
Journal of Pharmacy and Pharmacology, ISSN 0022-3573, 11/2016, Volume 68, Issue 11, pp. 1359 - 1365
Objectives Raltegravir is a human immunodeficiency virus (HIV)-1 integrase strand transfer inhibitor currently marketed at a dose of 400 mg twice daily (BID).... 
interaction | pharmacokinetics | calcium carbonate | aluminium and magnesium hydroxide | once-daily | ACID-REDUCING AGENTS | THERAPY | VOLUNTEERS | PHARMACOLOGY & PHARMACY | HIV-INTEGRASE INHIBITOR | Raltegravir Potassium - adverse effects | Area Under Curve | Magnesium - administration & dosage | Humans | Middle Aged | Raltegravir Potassium - administration & dosage | Male | Metabolic Clearance Rate | Aluminum Hydroxide - administration & dosage | HIV Integrase Inhibitors - administration & dosage | Drug Interactions | Polypharmacy | Antacids - adverse effects | HIV Infections - diagnosis | Adult | Female | Calcium Carbonate - administration & dosage | Magnesium - adverse effects | Raltegravir Potassium - pharmacokinetics | Drug Administration Schedule | Administration, Oral | HIV Infections - virology | HIV Integrase Inhibitors - pharmacokinetics | Magnesium Hydroxide - adverse effects | Calcium Carbonate - adverse effects | Aluminum Hydroxide - adverse effects | Magnesium Hydroxide - administration & dosage | HIV Integrase Inhibitors - adverse effects | Raltegravir Potassium - blood | HIV Infections - drug therapy | HIV Integrase Inhibitors - blood | Antacids - administration & dosage | Drug Combinations | Urine | Antiviral agents | Analysis | Electrocardiogram | Calcium carbonate | Electrocardiography | Magnesium hydroxide | HIV (Viruses) | Human immunodeficiency virus--HIV | Antacids | Magnesium
Journal Article
Journal of Clinical Virology, ISSN 1386-6532, 2016, Volume 87, pp. 30 - 36
Journal Article
Journal Article
Journal Article